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Abstract 
Few would have thought that in this century, a new coronavirus called SARS-CoV-2 would kill many 
people around the world, cripple the economy, and leave the medical staff helpless. Severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus that first appeared in Wuhan, China, and 
spread rapidly around the world, and strict quarantines did not prevent the severe prevalence from 
spreading worldwide. Antiviral drugs do not work well enough for everyone. The mortality rate in the 
world is still significant. The only thing that gives hope to the people of the world is the hope of being 
vaccinated, so by producing vaccines in the shortest possible time, science has once again saved 
humanity. Thus, from the very beginning, pharmaceutical companies started to produce safe vaccines. 
Currently, more than 200 types of vaccines around the world are undergoing various stages of 
production, and about 30 vaccines have entered the clinical trial phase, of which 9 vaccines have 
entered phase 1 to 3 of clinical trials. DNA and RNA-based vaccines were first developed and were not 
licensed before coronavirus disease 2019 (COVID-19). Other types of vaccines, including non-
replicating viral vectors as well as inactivated vaccines, are undergoing clinical phases. There are 
currently 9 common vaccines Inovio Pharmaceuticals, Moderna, BioNTech/Pfizer, AstraZeneca, 
CanSino Biological, Gam-COVID-Vac (Sputnik V), Wuhan Institute of Biological Products/Sinopharm, 
Beijing Institute of Biological Products/Sinopharm, and Sinovac Institutes in the world. Vaccination 
with the Pfizer vaccine, which is approved by the World Health Organization (WHO), is underway in 
many countries. The WHO predicts that by the end of 2021, one billion people worldwide will be 
vaccinated by the company.  
Keywords: SARS-CoV-2, COVID-19, Vaccine, Pfizer, Moderna, AstraZeneca 
 
1. Introduction 
Almost one year has passed since the emergence 
of the deadly coronavirus. The virus was first identified 
in 2019 in Wuhan, China. The virus has spread rapidly 
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around the world, killing many people every day [1, 2]. 
According to official sources, 106 million people have 
been infected with the virus, of which 59 million have 
been identified and about 2 million have died. 
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Coronavirus disease 2019 (COVID-19) disease which 
is caused by severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV-2), covers a wide range of 
clinical symptoms, from mild symptoms such as mild 
flu to severe symptoms such as acute respiratory 
distress syndrome (ARDS) followed by pneumonia 
and death. It should be noted that flock safety is 
possible by gaining natural immunity through 
infection, but the losses and consequences can be 
irreparable [3]. Swedish authorities believed that with 
60% of the population affected, herd immunity could 
be effective in controlling the disease, a hypothesis that 
was ineffective and that the death rate in Sweden was 
five times higher than in Germany [4]. Thus, the 
production of an effective vaccine against the disease 
was prioritized and is considered as the only practical 
way to establish herd safety. The incubation period of 
COVID-19 is estimated to be 5 days and the onset of 
symptoms at 11.5 days [5]. Studies show that patients 
with COVID-19 excrete the highest levels of viral 
nucleic acid (RNA) at the onset of symptoms [6]. 
These and other epidemiological data suggest disease 
transmission in a pre-symptom period [7]. It takes two 
weeks for the severe symptoms of the disease to appear 
followed by a cytokine storm created by immunity 
which causes widespread inflammation and diffuse 
intravascular coagulation [8, 9]. Studies showed the 
mortality rate of this disease in patients is age-related. 
A high percentage of people over the age of seventy 
who have an underlying disease is dying. Other factors 
such as high blood pressure, obesity, diabetes as well 
as gender (male > female) affect the severity of the 
disease [10-12]. Some anti-CoV candidate drugs 
should be analyzed as preclinical compounds for the 
potential treatment of COVID-19. A small number of 
COVID-19 candidate drugs have reached phase 3 
clinical trials such as ritonavir, cobicistat, lopinavir, 
darunavir, remdesivir, HIV protease inhibitor 
(ASC09F), and oseltamivir [13]. Inhibitors of the 
SARS-CoV or Middle East respiratory syndrome 
(MERS) that were previously available, are being 
investigated [14]. Many institutions around the world 
have been working from the beginning to develop an 
effective vaccine against COVID-19. In August 2020, 
more than 200 candidate vaccines were introduced at 
different stages of development. While about 30 
vaccines are currently in clinical trials, the 9 vaccines 
that have entered phase 1 clinical trials since mid-May 
2020 will include AstraZeneca/Oxford’s AZD1222 and 
Moderna’s mRNA-1273 vaccines. mRNA-1273 in the 
Moderna vaccine encodes the S protein [15]. S protein 
is released, which stimulates cellular and humoral 
immune responses. Earlier, RNA interference 
technique was used in the treatment of SARS and 
MERS, but it did not reach the vaccine production 
stage [16]. mRNA vaccines are a suitable alternative to 
existing vaccines due to their high efficacy, appropriate 
immune response, high production rate, harmless 
administration, and easy processing [17]. In general, 
vaccines work by training the immune system to 
identify the part of the virus that causes the disease. In 
the traditional method, the inactivated virus was used 
to make the vaccine, but in the case of the mRNA 
vaccine, the situation is different because instead of 
injecting the viral protein, the person receives the 
genetic material (mRNA) that encodes the viral 
protein. When these genetic instructions are injected 
into the arms, the muscle cells translate these codes to 
make viral proteins directly in the body. The mRNA 
vaccine encodes only an important fragment of a viral 
protein. mRNAs show the immune system what the 
real virus will cause in the body, and this preview will 
allow the immune system to design powerful 
antibodies and elicit an appropriate immune 
response. mRNA is not transmitted to the next 
generation [18]. Given the massive COVID-19 
pandemic, production capacity soon will certainly not 
be able to meet global demand for the vaccine in all 
countries, so vaccination is a priority for medical staff 
and susceptible individuals. It is estimated that by the 
end of 2021, the vaccine will be available worldwide to 
the rest of the population. Accuracy and sensitivity in 
performing preclinical and clinical trials in order to 
produce a safe and effective vaccine is of great 
importance in order to prevent severe side effects in 
individuals [19]. The process of producing a new 
vaccine is long and usually takes 10 to 15 years. Before 
to COVID-19, the mumps vaccine was the fastest 
vaccine produced and used in 5 years. Thus, producing 
a vaccine against COVID-19 over a period of one to two 
years is a challenge that researchers have finally been 
able to accomplish. The exploratory phase is the first 
step in the vaccine production process, which involves 
preliminary laboratory research that involves 
identifying the structure and genetics of the virus. The 
second phase is a pre-clinical studies in which 
experiments are performed on an animal model such 
as a mouse to evaluate the immune response of the 
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candidate vaccine and its advantages and 
disadvantages. Clinical trials are performed on 
humans after the safety and efficacy of the vaccine 
have been demonstrated in animal models. Clinical 
trials in humans are performed in three phases. In 
phase 1 (Safety), the vaccine is injected into a small 
number of healthy and immunocompetent 
individuals. In phase two (Expanded Safety), the 
vaccine is tested on hundreds of people in different 
groups. At this stage, should be evaluated the immune 
response, appropriate dose, and distance between 
doses. Phase 2 confirms the safety of the vaccine and 
you can also determine the appropriate dose to test in 
phase 3. In Phase 3 (Efficacy) clinical trials in humans, 
the vaccine is tested on a large scale in thousands of 
people. In this step, will be evaluated the effect of the 
vaccine [20]. There are various platforms being looked 
at for the development of COVID-19 vaccines. These 
include RNA, DNA, nonreplicating viral vectors and 
inactivated vaccines. 
 
2. RNA-based vaccines 
The RNA-based platform, developed by Moderna 
and Pfizer/BioNTech companies, is a candidate in 
clinical trials and is in phase 3 clinical trials. The type 
of candidate vaccine for both Moderna and Pfizer is 
lipid nanoparticle [LNP] encapsulated mRNA. The 
target antigen in both of them is spike protein, as well 
as multiple doses. They will also trigger both humoral 
and cellular immune responses. Their advantage is 
that they are made using genetic sequencing and do 
not need to be cell-cultured. One of their 
disadvantages is that LNP is temperature-sensitive, 
and no RNA-based vaccine has been developed so far. 
Currently, both vaccines are approved by the US 
government [21, 22]. 
 
3. DNA-based vaccines 
DNA-based vaccines encode the target antigen 
and produce a persistent immune response. 
Transfected cells continuously produce certain 
transgenic proteins. DNA vaccines are temperature 
stable, but their safety and efficacy require further 
research. Administration of DNA vaccines may also 
cause mutations and integration of the host gene [23]. 
The DNA-based platform, developed by Inovio 
Pharmaceuticals (an American biotechnology 
company), is a candidate in clinical trials and is in 
phases 1 and 2 clinical trials. The type of candidate 
vaccine for Inovio Pharmaceuticals is DNA plasmid 
vaccine with electroporation. The vaccine, called INO-
4800, is injected intradermally followed by 
electroporation to ensure that it is absorbed into the 
cell. The target antigen in these vaccines, such as RNA-
based vaccines, is spike protein, as well as multiple 
doses. They will also trigger both humoral and cellular 
immune responses. The most important advantage of 
this type of vaccine is that electroporation produces a 
strong immune response and does not require cell 
culture. One of the disadvantages of the DNA-based 
vaccine is that electroporation, although safe, can 
potentially be problematic, and no DNA-based vaccine 
has been developed in the past [24, 25].  
  
4. Non-replicating viral vector vaccines 
The Non-replicating Viral Vector platform, 
developed by the AstraZeneca/University of Oxford 
and CanSino Biological Inc/Beijing Institute of 
Biotechnology, and both are in phase 3 and phase 2 
clinical trials, respectively. The type of candidate 
vaccine for AstraZeneca is AZD1222 and for CanSino 
is Adenovirus type 5 vector. Both AstraZeneca and 
CanSino utilize adenovirus as a vector for their 
COVID-19 vaccine. The target antigen in both vaccines 
is spike protein, and the AstraZeneca vaccine is a single 
dose. They will also trigger both humoral and cellular 
immune responses. The advantage of the non-
replicating viral vector vaccine of AstraZeneca is that it 
can be produced on a large scale and provides an 
effective immune response, as previously 
demonstrated in the case of Ebola. One of the 
disadvantages of the AstraZeneca vaccine from the 
University of Oxford is that the available immunity can 
disrupt clinical use and reduce the immune response. 
CanSino and AstraZeneca intend to offer their 
vaccines at a low cost, which, given their moderate 
effectiveness, may be beneficial to some countries [26-
28]. Gam-COVID-Vac (Sputnik V) from Russia is a 
heterologous recombinant adenovirus (rAd)-based 
vaccine. The immunity of the vaccine is satisfactory 
and produces a strong humoral and cellular immune 
response and its efficacy is 92% [29].  
 
5. Inactivated vaccines 
The Inactivated platform, developed by Wuhan 
Institute of Biological Products/Sinopharm, Beijing 
Institute of Biological Products/Sinopharm, and 
Sinovac Institutes. They are all in phase 3 clinical 
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trials. The type of candidate vaccine for Wuhan 
Institute is inactivated and for Sinovac Institutes is 
inactivated aluminum adjuvant. The target antigen in 
the vaccine produced by these three institutes is the 
whole virus, and the only Wuhan Institute is the 
multiple-dose. The immune response created by the 
Wuhan Institute vaccine is more humoral, and also the 
immune response at the Sinovac Institute is mostly 
humoral, which will increase in the presence of 
aluminum adjuvant. The advantage of using the 
Wuhan Institute inactived vaccine is that, due to the 
use of the inactive virus, the pathogen is killed and 
there is no risk of recurrence [30, 31]. 
 
6. Conclusion 
In this short review, we discuss ways that can 
prevent the deadly spread of COVID-19 worldwide, 
including drug therapy and vaccine use. Eventually, 
the efforts of researchers around the world led to the 
development of effective vaccines against COVID-19 to 
be the sweet end to the most terrible nightmare of the 
21st century. Of course, vaccination should be done by 
adopting policies not only in rich countries, but in all 
countries regardless of nationality, religion, color, and 
race, and governments should do their best for the 
health of the people. Predictably, the only way to 
control COVID-19 before vaccination by countries is to 
use new antiviral drugs, social distancing, using 
facemasks, and regular handwashing with soap and 
water and if soap and water are not readily available 
and hands are not visibly dirty, use a hand sanitizer 
that contains at least 60% alcohol. Currently, the 
BNT162b2 vaccine from Pfizer/BioNTech 
pharmaceutical companies with 90% efficiency and 
mRNA-1273 vaccine from Moderna company has 
been approved by the US government and is being 
vaccinated with the Pfizer vaccine in the United States, 
many European countries, and several Asian countries 
[21]. The most important challenge for mRNA vaccine 
production is its inherent instability, as it is more likely 
to degrade above freezing temperature. 
Pfizer/BioNTech mRNA vaccines require optimal 
storage at minus 94 Fahrenheit degree and are 
destroyed in about five days at room temperature 
slightly above freezing. In contrast, Moderna 
Pharmaceuticals claims that their vaccine can be 
stored at most home temperatures or medical freezers 
for up to six months for long-term transportation and 
storage.  The AstraZeneca vaccine, despite being less 
effective (70%) than its competitors such as Pfizer and 
Moderna, can be used in standard refrigerated 
conditions between 36 and 46 Fahrenheit degree for 
at least six months for storage and transportation, 
which is a valuable advantage over two The vaccine 
rivals Pfizer and Moderna and will be easier to use in 
developing countries [22]. Pharmaceutical companies 
Pfizer and Moderna have not joined the COVAX 
initiative, but AstraZeneca has agreed to provide 
lower-cost vaccines to middle-income countries. For 
all COVID-19 vaccine candidates, we have only 
preliminary information on a small number of 
infections, and none of the COVID-19 vaccine-
producing groups have released complete information 
so far, so it is difficult to fully assess the differences 
between them. However, for evaluating the 
effectiveness of all COVID-19 vaccines to control the 
pandemic of this disease, we must wait for more 
follow-up and long-term data.  
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